The embryonic pattern of global DNA methylation is first established in the inner cell mass (ICM) of the mouse blastocyst. The methyl donor S-adenosylmethionine (SAM) is produced in most cells through the folate cycle, but only a few cell types generate SAM from betaine (N, N,N-trimethylglycine) via betaine-homocysteine methyltransferase (BHMT), which is expressed in the mouse ICM. Here, mean ICM cell numbers decreased from 18-19 in controls to 11-13 when the folate cycle was inhibited by the antifolate methotrexate and to 12-14 when BHMT expression was knocked down by antisense morpholinos. Inhibiting both pathways, however, much more severely affected ICM development (7-8 cells). Total SAM levels in mouse blastocysts decreased significantly only when both pathways were inhibited (from 3.1 to 1.6 pmol/100 blastocysts). DNA methylation, detected as 5-methylcytosine (5-MeC) immunofluorescence in isolated ICMs, was minimally affected by inhibition of either pathway alone but decreased by at least 45-55% when both BHMT and the folate cycle were inhibited simultaneously. Effects on cell numbers and 5-MeC levels in the ICM were completely rescued by methionine (immediate SAM precursor) or SAM. Both the folate cycle and betaine/BHMT appear to contribute to a methyl pool required for normal ICM development and establishing initial embryonic DNA methylation. THE FINAL STAGE OF THE MAMMALIAN preimplantation embryo before it implants in the uterus is the blastocyst. The blastocyst develops from an undifferentiated morula by formation of a fluid-filled blastocoel cavity and differentiation of 2 initial cell lineages: the inner cell mass (ICM) and the trophectoderm (TE). The TE encloses the blastocoel and will differentiate into extraembryonic tissues, including the fetal portion of the placenta and the outermost trophoblast layer of the fetal membranes. The ICM lies within the blastocoel on the inner wall of the TE. Just before implantation, the ICM itself diverges into 2 lineages: the epiblast that will give rise to the fetus, umbilicus, and innermost fetal membranes; and the primitive endoderm that becomes the intermediate layers of the extraembryonic membranes (1-3).
THE FINAL STAGE OF THE MAMMALIAN preimplantation embryo before it implants in the uterus is the blastocyst. The blastocyst develops from an undifferentiated morula by formation of a fluid-filled blastocoel cavity and differentiation of 2 initial cell lineages: the inner cell mass (ICM) and the trophectoderm (TE). The TE encloses the blastocoel and will differentiate into extraembryonic tissues, including the fetal portion of the placenta and the outermost trophoblast layer of the fetal membranes. The ICM lies within the blastocoel on the inner wall of the TE. Just before implantation, the ICM itself diverges into 2 lineages: the epiblast that will give rise to the fetus, umbilicus, and innermost fetal membranes; and the primitive endoderm that becomes the intermediate layers of the extraembryonic membranes (1) (2) (3) .
During early embryogenesis, genome-wide epigenetic reprogramming occurs wherein the gamete-specific patterns of DNA methylation are globally erased and replaced with the initial embryo-specific epigenome. Global DNA demethylation begins shortly after fertilization, with methylation reaching low levels in the morula and early blastocyst in mouse and human embryos (4-7). There are important exceptions to this general scheme, including imprinted genes and repetitive sequences that escape the postfertilization erasure and maintain methylation (8, 9) , but most of the genome becomes hypomethylated.
Widespread de novo methylation then reappears in the epiblast after implantation (4) (5) (6) (7) . The precise developmental stage where DNA methylation begins to increase is not fully known. However, the initial indication of increased methylation that has been reported in mouse is the reappearance of 5-methylcytosine (5-MeC) immunofluorescence at the blastocyst stage, where it is restricted to the nuclei of the ICM (7, 10, 11) . There may be species differences in this timing because in bovine embryos, it reappears in the late cleavage stages instead (12) . Recently, direct sequencing of the preimplantation and early postimplantation embryo methylome (4, 6) confirmed the general pattern of erasure followed by de novo methylation indicated by changes in 5-MeC immunofluorescence. Most methylated sequences appeared in postimplantation epiblast, however, indicating that a major portion of de novo methylation continues postimplantation. The identities of the initial methylated regions that are detected in the ICM by 5-MeC immunofluorescence remain unknown.
DNA methylation involves the addition of methyl groups to cytosine residues by DNA methyltransferases (3) . The universal methyl donor for these and most other methyltransferases is S-adenosylmethionine (SAM) (13) , which is produced through either of 2 known 1-carbon metabolic pathways in mammals (14, 15) . Almost all cells utilize the folate cycle to supply 1-carbon units as methyl groups. However, a few cell types also employ a mechanism that uses betaine (N,N,N-trimethylglycine) as the methyl donor. In the folate cycle, methyl groups are shuttled to homocysteine via 5-methyltetrahydrofolate. The transfer of a methyl group converts homocysteine to methionine that is further processed by addition of adenosine to yield SAM (16) (17) (18) . One-carbon groups carried on reduced folates are also required for the synthesis of thymidylate and purines (17, 19) . In the betaine-dependent pathway, the methyl group is instead donated by betaine and transferred directly to homocysteine by the enzyme betaine-homocysteine methyltransferase (BHMT; EC2.1.1.5) (14, 15, 20) .
A methyl pool is almost certainly produced by preimplantation embryos. Exogenously supplied methionine is converted to SAM by both mouse and bovine preimplantation embryos (21, 22) . Preimplantation embryos also likely have a fully functional folate cycle (15, 23) because all the relevant enzymes of 1-carbon metabolism are expressed in the embryos of several species (24, 25) , and inhibiting the folate cycle using the antifolate, methotrexate (MTX), causes preimplantation developmental arrest in vitro due to depletion of thymidylate and purines (25, 26) . Endogenous folates appear to be sufficient for preimplantation embryogenesis because exogenous folate is not required for the development of viable blastocysts from fertilized mammalian eggs in vitro (25, 26) . Nevertheless, preimplantation mouse embryos are able to take up folates via folate receptor-mediated endocytosis and thus replenish their folate pool (27) .
Although the folate cycle is nearly ubiquitous, the betaine-BHMT pathway had been considered significant in rodents only in the liver (28) . Unexpectedly, we recently found that BHMT is also active in the ICM of the mouse blastocyst and that mouse embryos accumulate high levels of betaine from the female tract (29, 30) . It is not known whether the DNA remethylation that apparently begins in the ICM requires methyl groups that are synthesized in the late preimplantation embryo either through the folate cycle or from betaine, nor whether this methyl pool is critical to blastocyst lineage and postimplantation development. Restricted methyl availability may contribute to the unexplained deleterious effects on the epigenome and on offspring that can occur from various stresses during the preimplantation period (9, (31) (32) (33) , particularly if DNA methylation is affected.
MATERIALS AND METHODS

Chemicals and media
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless specified. Embryo culture media were modified versions of KSOM (potassium-supplemented simplex-optimized medium) and HEPES-KSOM (34) with glutamine omitted and polyvinyl alcohol (1 mg/ml; cold-water soluble, MW 30-70 K) substituted for bovine serum albumin (BSA), producing basal embryo culture media containing no amino acids or nucleosides, except where these were added (see below). KSOM was equilibrated with 5% CO 2 /air. Fresh stocks were prepared in KSOM (1 mM MTX, 10 mM thymidine, 100 mM methionine, and 5 mM SAM) or 1 M NaOH (10 mM hypoxanthine).
Mouse embryos
Animal protocols were approved by the Animal Care Committees of the Ottawa Hospital Research Institute or the University of Ottawa Faculty of Medicine. Eight-cell embryos were obtained from female CF1 mice (4-7 wk old; Charles River Laboratories, Saint-Constant, QC, Canada) superovulated with eCG (5 IU) and human chorionic gonadotropin (hCG; 5 IU) ;47 h later, and caged overnight individually with B6D2F1 males (Charles River Laboratories). Eight-cell embryos were flushed from excised oviducts with HEPES-KSOM at ;67 h post-hCG and cultured for 48 h in KSOM drops under mineral oil in 5% CO 2 /air at 37°C (34) , which corresponds to late blastocysts with ;80 cells (see RESULTS). Images of embryos were recorded at the end of culture. In-vivo-produced 1-cell embryos, morulae, or blastocysts were obtained at ;21, ;76, or ;94 h post-hCG, respectively.
Morpholino and MTX treatments
Two nonoverlapping antisense morpholinos (MOs) (Gene Tools Limited Liability Company, Philomath, OR, USA) targeted Bhmt. BhmtMO1 (59-GTGCCATCTTTCCGGTGTAGTGAGT-39) targeted the start codon (underlined) region of murine Bhmt, and BhmtMO2 (GTGCCATCTTTCCGGTGTAGTGAGT) targeted 72-48 nt 59 from the start codon. A control morpholino (Con MO) (GTcCCATgTTTgCGGTcTAcTGAGT) had 5 mismatches (lowercase) compared to BhmtMO1. MO procedures and knockdown validation (;70% decrease) were previously described (29) . Eight-cell stage embryos were cultured for 48 h with MO (200 mM) and Lipofectin (6.25 ml/ml) as previously described (29, 35) . MTX at the concentrations specified was added to inhibit the folate cycle. Where indicated, hypoxanthine and thymidine (H+T) were added to overcome the effects of MTX on purine and thymidylate synthesis, as described below.
Differential cell counting and lineage determination in blastocysts fixed overnight (100% ethanol with 25 mg/ml bisbenzimide at 4°C) to label all nuclei with bisbenzimide. ICM (bisbenzimide only) and TE (bisbenzimide and propidium iodide) nuclei were visualized in slightly compressed blastocysts using conventional fluorescence microscopy (Leica DMLB with Chroma filter set 31000 for bisbenzimide and 41002 for propidium iodide; Leica Microsystems Incorporated, Buffalo Grove, IL, USA).
OCT4 (POU5FL, ICM specific) and NANOG (epiblast specific) were detected by immunofluorescence. Blastocysts were fixed (3.7% paraformaldehyde for 1 h), permeabilized (0.1% Triton X-100/0.3% BSA for 30 min), and blocked (0.3% BSA/ 0.01% Triton X-100 for 1 h) in PBS at room temperature and labeled with primary antibodies [1: 
ICM isolation
ICMs were isolated from blastocysts by immunosurgery as previously described (37, 38) . Zonae pellucidae were removed with Acid Tyrode and TE lysed by exposure to heat-inactivated (56°C for 30 min) rabbit anti-mouse serum (Sigma-Aldrich; M-5774) followed by guinea pig complement (Sigma-Aldrich; S-1639, 1:5 in KSOM), each for 10 min at 37°C. The ICM was isolated by repeated aspiration through a narrow-bore pipette.
5-MeC immunofluorescence
5-MeC was detected by immunofluorescence essentially as previously described (10) . Embryos or ICMs were fixed in 4% formaldehyde in PBS (15 min), permeabilized (0.2% Triton X-100 in PBS for 30 min), depurinated (4 N HCl and 0.1% Triton X-100 for 10 min), blocked overnight (2% BSA in PBS), and incubated with anti-5-MeC antibody (1:500, ABI-100; Eurogentec, AnaSpec, Incorporated, Fremont, CA, USA) in blocking solution (4°C overnight) followed by goat anti-mouse Alexa 488 (1:500 for 1 h at room temperature in the dark) and bisbenzimide (10 mg/ml for 10 min at room temperature). Imaging was done with a Leica DMLB microscope using Chroma filter sets 31000 (bisbenzimide) and 41001 (Alexa 488). Whole-mount fluorescence intensity was quantitated using ImageJ 1.4 (National Institues of Health, Bethesda, MD, USA) to draw a perimeter enclosing each blastocyst or isolated ICM and determine the average intensity within the enclosed area. The average intensity was used to normalize for variation in cell number. In each repeat, the average intensity of the control group was set to 100 to normalize for variability in immunofluorescence levels between repeats.
Determination of methylation status of Snrpn and H19 imprinting control regions
Methylation within the H19 and Snrpn imprinting control regions (ICRs) was measured in individual immunosurgically isolated ICMs by bisulfite mutagenesis as previously described for single oocytes (39) with modifications as follows. In brief, ICMs were simultaneously lysed and embedded in 3% low-melting point agarose (Sigma-Aldrich) beads, and bisulfite treatment was performed as described previously (39) . Amplification of the Snrpn and H19 ICRs was performed as described (31) , except that reactions were multiplexed with 2 sets of gene-specific primers. Negative controls (no ICM) were processed alongside each bisulfite reaction. First-round product (5 ml) was added into separate Snrpn and H19 second-round PCRs. PCR amplification and cloning were performed as previously described (39) . Approximately 30 ml of colony PCR was sent to Bio-Basic Incorporated (Markham, ON, Canada) for sequencing. Percent methylation was calculated as the number of methylated CpGs divided by total CpGs. Normally, Snrpn is methylated on the maternal allele and H19 on the paternal allele. Because the maternal and paternal alleles could not be distinguished in these assays, the expected level of methylation is ;50%, with methylation levels between 40 and 60% considered normal.
Measurement of SAM
A total of 100 blastocysts were frozen in each microcentrifuge tube using liquid nitrogen and stored at 280°C. Thawed samples were sonicated in 60 ml ice-cold aqueous buffer containing 4 mM ammonium acetate, 0.1% formic acid, and 0.1% heptafluorobutyric acid (pH 2.5). SAM was quantified by HPLC (40 ml sample injection volume) followed by mass spectrometry, as described previously (40) . S-Adenosylhomocysteine was undetectable above background in these small samples.
Embryo transfer
Female CD-1 recipients (8-15 wk old; Charles River Laboratories) were mated with vasectomized CD-1 males. Blastocysts (12) (13) (14) (15) (16) (17) (18) were transferred into these pseudopregnant females 2.5 d postcoitus using the NSET (Non-Surgical Embryo Transfer Device; ParaTechs, Lexington, KY, USA), according to the manufacturer's instructions. Recipients were killed on embryonic d 10.5 (E10.5).
Data analysis
Data were graphed and analyzed with Prism 5 (GraphPad Software, Incorporated, San Diego CA, USA). Data are presented as the mean 6 SEM. N indicates the number of independent repeats, and n indicates the total embryos where applicable. Comparisons were made by t test, ANOVA followed by the Tukey's multiple comparison test, or 2-way ANOVA. P , 0.05 was considered significant.
RESULTS
Effect of BHMT and folate cycle inhibition on blastocyst development and cell lineage allocation
We have previously validated antisense MOs that effectively knock down BHMT expression and activity in blastocysts (29) . Here, we used MTX, a well-characterized antifolate that targets the key folate cycle enzyme dihydrofolate reductase (41) , to disrupt the folate cycle. This rapidly depletes intracellular tetrahydrofolate and 5-methyltetrahydrofolate (42, 43) and thus blocks homocysteine remethylation. Inhibition of the folate cycle with MTX also blocks purine and thymidylate synthesis. This lethal effect can be circumvented with exogenous thymidine and purine (hypoxanthine) while still rapidly depleting folates and selectively targeting SAM synthesis (44) , as previously shown for murine, bovine, and ovine embryos (25, 26) . We had also attempted to knock down expression of the key folate cycle enzyme specific to SAM synthesis, methylenetetrahydrofolate reductase (MTHFR) (45) , with antisense MOs, but protein levels were only slightly decreased (data not shown), probably due to the persistence of maternal MTHFR protein in blastocysts. Thus, our strategy here was to use MTX to target the folate cycle in conjunction with BHMT knockdown using established antisense MOs.
We first optimized conditions for targeting the folate cycle with MTX while rescuing the effects on purine and thymidylate synthesis using exogenous H+T. Up to 1 mM each of H+T did not affect blastocyst development or TE and ICM cell numbers (Fig. 1A, B) . Blastocyst development was not reduced by up to 1 mM MTX when 1 mM each of H+T was present but was completely suppressed by 10-fold less MTX without H+T (Fig. 1C) . The effect on both ICM and TE cell number was also much less severe with H+T than without (Fig.  1D) . Thus, 1 mM MTX with 1 mM H+T was used in further experiments to inhibit SAM synthesis by the folate cycle.
Because neither knocking down BHMT in blastocysts (29) nor inhibiting the folate cycle with MTX in the presence of H+T ( Fig. 1 ) had a profound effect on blastocyst development by themselves, we blocked both pathways simultaneously to investigate whether they might function in parallel. Blastocyst development from the 8-cell stage was not affected by MTX in the presence of Con MO ( Fig. 2A) .
BHMT knockdown alone (BhmtMO1 at 0 mM MTX) decreased development by a moderate amount, as previously shown (29) . Both treatments simultaneously (BhmtMO1 with 1 mM MTX), however, further decreased development significantly ( Fig. 2A) .
MTX and BHMT knockdown had distinct effects on the ICM and TE cell lineages. TE cell number determined by differential cell counting was reduced with increasing amounts of MTX but was not affected by BHMT knockdown. In contrast, ICM cell number was decreased by either MTX or BHMT knockdown independently and significantly further decreased by both treatments together (Fig. 2B) . Comparable results (Fig. 2C, D) were obtained using the second Bhmt MO (BhmtMO2). As an independent means of counting ICM cells, we used OCT4 immunofluorescence and also counted the subset of ICM cells in the epiblast lineage by NANOG immunofluorescence (Fig. 2E, F) . The number of OCT4-positive nuclei was essentially the same as the number of ICM cells determined by differential cell counting (cf. Fig. 2B, D) . The decrease in the number of OCT4-positive cells with BhmtMO2 and further decrease with both BhmtMO2 and MTX together (Fig. 2F ) mirrored the results with differential cell counting. The NANOG-positive subset of ICM cells was also decreased by BhmtMO2 and further decreased by simultaneous MTX and BhmtMO2 (Fig. 2F ), indicating that epiblast was affected. 
SAM levels in blastocysts
Control blastocysts contained approximately 3 pmol SAM/ 100 blastocysts (Fig. 3) . Blastocysts treated with BHMT MO or MTX alone had SAM levels that did not differ significantly from controls, although MTX caused a trend toward a decrease. However, total SAM content was significantly lowered (by ;50%) in blastocysts in which BHMT had been knocked down and the folate cycle inhibited with MTX simultaneously (Fig. 3) .
5-MeC immunofluorescence in blastocysts
We next determined whether BHMT knockdown or inhibition of SAM synthesis via the folate cycle affected 5-MeC immunofluorescence at the blastocyst stage. Knocking down BHMT with BhmtMO1 or inhibiting folate metabolism with MTX had no noticeable effect on the appearance of 5-MeC in the ICM when compared to control embryos (Fig. 4A) . However, with simultaneous BHMT knockdown and folate cycle inhibition, 5-MeC staining of the ICM became nearly indistinguishable from the lower level of fluorescence in TE (Fig. 4A) . Quantification of the mean fluorescence intensity over the whole blastocyst indicated that 5-MeC was significantly decreased in blastocysts with MTX and BhmtMO1 together, but not with either alone (Fig. 4B) . Because 5-MeC levels were most severely affected in the ICM, we assessed 5-MeC in the ICM that had been isolated by immunosurgery. Knocking down BHMT or inhibiting SAM synthesis via the folate cycle alone in blastocysts only slightly decreased 5-MeC levels in the isolated ICM (Fig. 5) . In contrast, 5-MeC was again substantially decreased in the ICM when both pathways were perturbed. Each antisense Bhmt MO had a similar effect (Fig. 5B) .
We also assessed the methylation status of the ICRs of 2 well-characterized imprinted genes, Snrpn and H19, whose methylation was previously shown to be susceptible to perturbation by in vitro culture (31), in immunosurgically isolated ICMs from control blastocysts (Con MO) and blastocysts where BHMT had been knocked down and the folate cycle inhibited (BhmtMO1 and MTX). Normal methylation levels were observed for Snrpn in 4 of 7 control and 6 of 10 BhmtMO1 plus MTX-treated ICMs and for H19 in 7 of 8 control and 7 of 10 BhmtMO1 plus MTX-treated ICMs. The remaining ICM in both groups exhibited some methylation loss, likely attributable to the effect of in vitro embryo culture (31) . The mean methylation at the Snrpn ICR was 41 6 3% (mean 6 SEM, N = 7) for control ICM and 40 6 2% (N = 10) for ICM where both pathways were perturbed (P = 0.85, t test; data sets in Supplemental Fig.  S1A) . Likewise, the mean methylation at the H19 ICR was 46 6 2% (N = 8) for control vs. 45 6 2% for the treated ICM (N = 10; P = 0.65; Supplemental Fig. S1B) . Thus, DNA methylation at these loci in the ICM as assessed by bisulfite sequencing was not perturbed by simultaneous BHMT knockdown and folate cycle inhibition.
Rescue by remethylation products
It was possible that the effects on blastocyst development and 5-MeC levels were due to incomplete rescue by H+T or MTX toxicity. We therefore attempted to rescue the detrimental effects with exogenous methionine, the direct product of homocysteine remethylation. Met is taken up via active transport into both TE and ICM (46) and is converted into SAM in blastocysts (21) . Methionine (0.2 mM) rescued blastocyst development and reversed the decrease in ICM and TE cell numbers (Fig. 6A, B) . Most strikingly, 5-MeC immunofluorescence in the ICM was completely restored by methionine (Fig. 6C) . We next attempted rescue by supplying exogenous SAM (0.2 mM). SAM similarly rescued development from the 8-cell to blastocyst stages when both BHMT and the folate cycle were perturbed (Fig. 7A) . SAM completely restored total ICM (OCT4-positive) and epiblast (NANOG-positive) cell numbers and partially restored TE cell number (Fig. 7B) . Finally, 5-MeC levels assessed in isolated ICMs were also restored by SAM (Fig. 7C ).
Postimplantation development
Embryos cultured from the 8-cell to blastocyst stages in 4 treatment groups (BhmtMO1 antisense MO or Con MO, each with or without MTX) were transferred to pseudopregnant recipients (5-9 recipients per treatment, 12-18 blastocysts per recipient). Fetuses, placentas, and resorption sites were examined on E10.5, when fetuses and placentas could be assessed separately. The implantation rate was significantly decreased only when both pathways were perturbed (Fig. 8A, H) . The fraction of transferred blastocysts that resulted in fetuses on E10.5 was not significantly decreased by BMHT knockdown alone but was lower in both MTX groups (Fig. 8B, H) . Decreased fetal numbers were due mainly to increased resorption of MTXtreated embryos that had implanted (Fig. 8C, D) . Fetal weight, crown-rump length, and placental weight were determined for all treatment groups, although very few fetuses were available in the BhmtMO plus MTX group (;4% of embryos transferred survived to become fetuses on E10.5; Fig. 8B ), providing limited material for analysis. Nevertheless, when the surviving fetuses were assessed, those in all 3 treatment groups exhibited significantly decreased mean fetal weights, crown-rump lengths, and placental weights compared with control ( Fig. 8E-G) .
DISCUSSION
Both the folate cycle and the betaine-BHMT pathway appear to contribute to SAM production that is required for de novo global DNA remethylation in the mouse ICM as detected by 5-MeC immunofluorescence. Inhibiting either pathway alone produced only minimal reductions in 5-MeC, but when both pathways were disrupted, 5-MeC levels in the ICM were substantially decreased. These effects appear to be specifically due to inhibition of SAM production, rather than nonspecific or toxic effects, because addition of either the direct SAM precursor methionine or SAM to the medium rescued global 5-MeC levels in the ICM. This interpretation is consistent with the effects in bovine embryos of directly blocking methionine conversion to SAM with ethionine, where 5-MeC levels were also reduced (22) . Therefore, we propose that, unlike virtually all nonhepatic cells, the mouse ICM has 2 pathways for SAM production that are at least partly redundant. A robust capacity to produce SAM may be necessitated by the large demand imposed by global DNA remethylation in the mouse epiblast. In addition, there may be other increases in demand on the methyl pool at the blastocyst stage because new histone methylation patterns become established in both the ICM and TE at the blastocyst stage (47) and are involved in ICM lineage allocation (48) . The increased metabolic activity in blastocysts also may require methyl groups to supply many of the approximately 1% of proteins in mammals that are predicted to be methyltransferases (49) .
The effects of BHMT knockdown and folate cycle inhibition on development to the blastocyst stage and on cell numbers in each lineage were also consistent with the hypothesis that the folate cycle is active in both the TE and ICM, whereas BHMT is restricted only to the ICM because only MTX had an effect on TE, whereas both MTX and BHMT knockdown affected the ICM. Decreased blastocyst development and reduced cell numbers are likely independent of any perturbations to global DNA remethylation because remethylation in the ICM occurs late in the blastocyst stage after the ICM has formed, does not occur in the TE, and knockout of zygotic DNA methyltransferases Dnmt1, Dnmt3a, and Dnmt3b does not prevent formation of the cell lineages in blastocysts (50) . Instead, a restricted supply of SAM may impair the development of each lineage by reducing the methyl pool available for the various other methyl-requiring biochemical pathways in the blastocyst.
Embryo transfer experiments indicated that inhibition of both the BHMT and folate-dependent SAM-generating pathways substantially decreased implantation as assessed by the number of resorption sites and fetuses present on E10.5, but there was no significant effect of inhibiting each pathway alone. This is consistent with the more severe effects of inhibition of both pathways on both cell number and 5-MeC levels in the ICM. However, once embryos had implanted and developed long enough to be present as either fetuses or resorption sites on E10.5, embryos from both groups where the folate cycle had been inhibited with MTX were much more likely to be resorbed. This may reflect impairment of placental function because our results indicate that TE, which gives rise to the fetal compartment of the placenta, relies on the folate cycle alone, and TE cell number was particularly sensitive to MTX. A) The number of blastocysts that implanted in the recipient uterus and continued to develop sufficiently to be detected on E10.5 was assessed, and implantation rate was calculated as the number of fetuses plus resorption sites divided by number of embryos transferred. B) Development of fetuses from blastocysts on E10.5 (% fetuses/blastocysts transferred). C) Fetal development (% fetuses/total implantations). D) Resorption sites evident on E10.5 (% resorptions/total implantations). E) Weights of fetuses recovered in grams. F) Weights of placentas recovered in grams. G) Crown-rump length of fetuses recovered in millimeters. In (A)-(G), means (6SEM) represented by bars that do not share the same letters are significantly different: ANOVA, Tukey's: P , 0.05 for (A), (B), and (F); P , 0.01 for (C) and (D); and P , 0.001 for (E) and (G). There were N = 5-9 recipients per group as follows: Con MO, no MTX, 5 recipients with 39 fetuses and 40 placentas successfully recovered for fetal weight, crown-rump length measurement, and placental weight; BhmtMO1, no MTX, 5 recipients, 28 fetuses, and 29 placentas; Con MO, plus MTX, 7 recipients, 14 fetuses, and 14 placentas; and BhmtMO1 plus MTX, 9 recipients, 6 fetuses, and 6 placentas. Note that a larger number of embryo transfers was performed for the latter 2 groups to attempt to obtain enough fetuses and placentas for measurements, although the low implantation rate and development of fetuses per embryo transferred (A, B) still resulted in a smaller number being available for measurements. H) Examples of uteri before dissection (upper panels), and fetuses (F), placentae (P), and resorption sites (R) (lower panels) for each treatment. Each lower panel shows the material recovered from the uterus in the upper panel. With nonsurgical embryo transfer, embryos are transferred into only 1 uterine horn. Scale bars, 1 cm.
Mice lacking a functional Bhmt gene are fertile (51) . Similarly, mice lacking the Mthfr gene and thus unable to produce SAM through the folate cycle are viable on some genetic backgrounds, and these are fertile (52) . Thus, there does not appear to be an absolute requirement for either a functional folate cycle or BHMT activity alone for embryos to develop through the blastocyst stage in vivo and develop normal fetuses and placentae. This is consistent with our conclusion here that BHMT and the folate cycle can each compensate at least in part when the other is perturbed. It is also possible that external methionine may be taken up by the embryo from the maternal reproductive tract in vivo to compensate for impaired homocysteine remethylation, similar to the methionine rescue that we demonstrated in vitro.
Relatively mild stress during preimplantation development can result in substantial dysregulation of a number of imprinted genes that are differentially methylated between the maternal and paternal alleles, leading to aberrant hypomethylation of the normally methylated allele (8) . DNA methyltransferase activity is required to maintain imprinted gene methylation during preimplantation development (53) (54) (55) , implying a requirement for SAM in imprinting maintenance. Surprisingly, the methylation status of H19 and Snrpn was unaffected in the ICM even when both pathways for SAM production were inhibited, despite the apparent loss of overall 5-MeC immunofluorescence. These results potentially indicate either that the methylation patterns of at least these 2 imprinted genes are stable in the blastocyst or that DNA methylation at imprinted domains is preferentially maintained when there is reduced availability of SAM. Because deletion or depletion of DNMT1o/DNMT1s during preimplantation development resulted in the loss of imprinted methylation (55, 56) , the latter explanation is favored, although this remains to be investigated.
Despite the recent focus of investigations on imprinted genes, a more global epigenetic instability may result from suboptimal conditions during preimplantation embryogenesis that is not restricted just to the subset of differentially methylated imprinted genes (8) . We propose that during late preimplantation and early postimplantation development, it may be DNA remethylation in the ICM and early epiblast, which probably requires a very substantial flux of methyl groups through the SAM pool, that is most susceptible to conditions that restrict SAM production. The resulting perturbation of embryonic epigenetic marks in the genome may underlie some of the reported negative sequelae of embryo culture stress, techniques of assisted reproductive technologies, and adverse maternal nutrition during the peri-implantation period.
